LeMaitre Q2 sales up 19% to $50.1M; EPS $0.36 (+127%); FY23 guidance raised; $0.14 dividend

LEMAITRE VASCULAR INC

2023-Q2 EPS reported $0.63 revenue$97,190,000

Sales $50.1M, +19% (+16% organic) vs Q2 2022; operating income $9.5M (+63%).
Net income $8.1M (+130%), diluted EPS $0.36 (+127%); adjusted EPS +25%.
Gross margin 64.0% (down from 66.0%); EMEA +26%, APAC +21%, Americas +16%.
FY23 guidance: sales $193M–$197.8M (+21%/+18% organic), EPS $1.23–$1.34 (ex-special $1.25–$1.35).
Quarterly dividend $0.14/share, payable Aug 31, record Aug 17; $25M buyback authorized.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

LEMAITRE VASCULAR INC reported the quarter ended June 30, 2023 results: revenue $50.1mm, net income $8.1mm, EPS $0.36. Guidance initiated.

Period: the quarter ended June 30, 2023
Revenue: $50.1mm
Net income: $8.1mm
EPS: $0.36
Guidance: initiated
Result: preliminary results

Exact text from the filing

of vascular devices, implants and services, today reported Q2 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q2 2023 Financial Results ● Sales $50.1mm, +19% (+16% organic) vs. Q2 2022 ● Op. income $9.5mm, +63% (+8% adjusted) ● Op. margin 19% ● Net income $8.1mm, +130% (+27% adjusted) ● Earnings per diluted share $0.36, +127%

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

LEMAITRE VASCULAR INC filing history →

Source: SEC EDGAR

accession 0001437749-23-021414

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.